Cantor Fitzgerald Reiterates Neutral Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “neutral” rating reaffirmed by Cantor Fitzgerald in a research note issued to investors on Monday, Marketbeat reports. They presently have a $9.00 price objective on the biotechnology company’s stock, down from their prior price objective of $55.00. Cantor Fitzgerald’s price objective points to a potential downside of 0.33% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Mizuho reduced their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Stifel Nicolaus cut their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Wolfe Research began coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $11.00 price target on shares of uniQure in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, uniQure currently has an average rating of “Hold” and a consensus price target of $34.33.

uniQure Price Performance

uniQure stock opened at $9.03 on Monday. The company’s 50 day moving average is $22.86 and its two-hundred day moving average is $29.72. The firm has a market cap of $562.48 million, a PE ratio of -2.62 and a beta of 0.73. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 230.98% and a negative net margin of 1,236.00%. On average, research analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, CFO Christian Klemt sold 6,217 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $148,337.62. Following the transaction, the chief financial officer directly owned 211,513 shares of the company’s stock, valued at $5,046,700.18. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 12,378 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the sale, the chief executive officer directly owned 639,076 shares of the company’s stock, valued at approximately $15,248,353.36. This trade represents a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 50,598 shares of company stock valued at $1,248,588. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Large investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new position in uniQure during the fourth quarter worth approximately $209,000. Virtus Investment Advisers LLC raised its position in uniQure by 91.6% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 6,520 shares during the last quarter. SummitTX Capital L.P. boosted its stake in uniQure by 386.3% during the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock worth $663,000 after purchasing an additional 22,010 shares during the period. Suvretta Capital Management LLC purchased a new position in uniQure during the 4th quarter worth $29,116,000. Finally, Readystate Asset Management LP acquired a new position in uniQure in the fourth quarter valued at $8,652,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.